Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines

Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol. * A male or female between, and including, 18 and 45 years of age at the time of the first vaccination. * Written informed consent obtained from the subject. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * Have clinically normal laboratory values for creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), complete blood count (CBC) and differential at screening. * Be seronegative for human immunodeficiency virus-1 and 2 (HIV 1/2) antibodies, HBsAg and hepatitis C virus (HCV) antibodies. * Have anti HBs titre ≥ 10mIU/ml at screening. * If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series. Exclusion Criteria: * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose. * Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). * Any history of clinical malaria. * Known exposure to malaria parasites within the previous 12 months. * Planned travel to a malaria endemic region during the study period. * History of allergic reactions or anaphylaxis to previous immunizations. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Personal history of autoimmune disease or subjects who describe a first-degree relative with clearly documented autoimmune disease. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s). * Major congenital defects or serious chronic illness(es). * Acute disease at the time of enrolment. * History of any neurologic disorders or seizures. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * Hepatomegaly, right upper quadrant abdominal pain or tenderness. * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. * History of previous exposure to experimental products containing any component of the vaccines used in this study. * Pregnant or lactating female. * History of chronic alcohol consumption and/or drug abuse. * Female planning to become pregnant or planning to discontinue contraceptive precautions.